Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLX2853 in R/R AML or High-risk MDS
NCT03787498Phase 1Completed
- Sponsor
- Opna Bio
- Start
- Mar 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PLX2853 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Opna Bio. Primary endpoints: Treatment-related adverse events, Area under the concentration-time curve and 5 more. Started Mar 2019; status: completed.
02
Drugs
PLX2853
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03787498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03787498.